A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
Latest Information Update: 28 Jun 2025
At a glance
- Drugs Seralutinib (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms PROSERA
- Sponsors Gossamer Bio
Most Recent Events
- 16 Jun 2025 According to a Gossamer Bio media release, enrollment has been completed in this trial on June 11th, 2025.
- 04 Jun 2025 Status changed from recruiting to active, no longer recruiting.
- 15 May 2025 According to a Gossamer Bio media release, enrollment completion expected in early June, with closure of new patient screening. And topline results expected in february 2026.